RashmeePatilMD

Internal Medicine • McAllen, TX

CEO @ Pinnacle Clinical Research, Hepatologist, Principal Investigator

Join to view full profile

Dr. Patil is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Patil's full profile

Already have an account?

Office
2502 West Trenton Road
Ste 202
McAllen, TX 78504

Education & Training

Baylor College of MedicineFellowship, Transplant Hepatology, 2016 - 2017
Lutheran Medical CenterInternship, Internal Medicine, 2012 - 2015
St. George's University School of MedicineClass of 2012

Certifications & Licensure

TX State Medical License 2016 - 2026
NY State Medical License 2015 - 2017
American Board of Internal Medicine Internal Medicine

Clinical Trials

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis Start of enrollment: 2019 Mar 28
Active, not recruiting
Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis Start of enrollment: 2023 Dec 01
Recruiting
Phase 3
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry) Start of enrollment: 2021 Jul 30
Active, not recruiting
Phase 2
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) Start of enrollment: 2024 Mar 13
Recruiting
Phase 3
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) Start of enrollment: 2021 Aug 19
Recruiting
Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Join now to see all

Publications & Presentations

PubMed

88 citations
NAFLD-related hepatocellular carcinoma: The growing challenge.
Pir Ahmad Shah, Rashmee Patil, Stephen A Harrison
Hepatology. 2023-01-01
173 citations
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, Jörn M Schattenberg, Rohit Loomba
The New England Journal of Medicine. 2024-02-08
17 citations
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
Arun J Sanyal, Pierre Bedossa, Mandy Fraessdorf, Guy W Neff, Eric Lawitz
The New England Journal of Medicine. 2024-07-25